Lilly's Alimta among SMC's September recommendations
This article was originally published in Scrip
Executive Summary
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.